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had a low vitamin D intake. Zinc serum concentrations were 
below normal in 14% of patients, despite adequate intake. 
Folic acid serum concentrations and intake were elevated. 
Despite safe total protein and fat intake, arginine plasma 
concentrations and erythrocyte eicosapentaenoic acid were 
below reference values in 19 and 6% of patients, respectively. 
Low BMD (Z-score <–2) was slightly more prevalent in pa-
tients, but the lifetime fracture prevalence was comparable 
to the general population.  Conclusions: Dutch patients with 
PKU on long-term dietary treatment have a near normal nu-
trient status. Supplementation of micronutrients of which 
deficiency may be deleterious (e.g., vitamin D and selenium) 
should be considered. BMD warrants further investigation. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Phenylketonuria (PKU; MIM 261600) is an autoso-
mal recessive disorder of phenylalanine (Phe) metabo-
lism caused by a deficiency of the enzyme phenylalanine 
 Keywords 
 Phenylketonuria · Micronutrients · Essential fatty acids · 
Bone mineral density · Phenylalanine · Osteopenia · 
Osteoporosis 
 Abstract 
 Introduction: In phenylketonuria (PKU), a natural protein-re-
stricted dietary treatment prevents severe cognitive impair-
ment. Nutrient deficiencies may occur due to strict diet. This 
study is aimed at evaluating the dietary intake and blood 
concentrations of micronutrients and essential fatty acids 
(FA), bone mineral density (BMD) and fracture history in pa-
tients on long-term dietary treatment.  Methods: Sixty early 
diagnosed Dutch patients (aged 1–39 years) were included 
in a multi-center cross-sectional study. Their dietary intake, 
blood concentrations of micronutrients, FA, fracture history 
and BMD were assessed.  Results: Selenium dietary intake 
and serum concentrations were low in 14 and 46% of pa-
tients, respectively. The serum 25-OH vitamin D2 + D3 con-
centration was low in 14% of patients while 20% of patients 
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hydroxylase (PAH; EC 1.14.16.1), leading to severe cog-
nitive impairment due to the accumulation of Phe in the 
brain. With newborn screening and the early institution 
of dietary treatment, cognitive impairment caused by 
PKU has nearly been eliminated in developed countries 
 [1] . Based on the level of blood Phe at diagnosis, disease 
severity is classified as either classic or severe PKU 
( ≥ 1,200 μmol/L), mild to moderate PKU (600–1,200 
μmol/L), or mild hyperphenylalaninemia (360–600 
μmol/L). Treatment consists of restriction in dietary Phe 
intake (an essential amino acid [AA]) through a diet low 
in natural protein to achieve safe Phe blood concentra-
tions (age below 12 years <360 μmol/L, age  ≥ 12 years 
<600 μmol/L, during pregnancy <240 μmol/L)  [2] . 
 Severely affected patients tolerate <500 mg of Phe, which 
is <10 g of natural protein per day  [3, 4] . To guarantee a 
sufficient intake of daily protein, patients use designated 
Phe-free amino acid mixtures (AAM) containing most 
AA and other micronutrients. Different AAM are avail-
able, all with variable compositions. In some, the amount 
of added nutrients is calculated based on the needed dai-
ly calories, while in others advised intakes of protein/ki-
logram bodyweight is used to assess appropriate nutrient 
composition  [5] . Studies evaluating intake and deficien-
cies of nutrients in PKU reported variable nutrient in-
takes and blood concentrations  [6–8] . A minority of pa-
tients is responsive to a recently available (2009) treat-
ment with tetrahydrobiopterin (BH4), a cofactor of PAH. 
BH4 increases the dietary Phe tolerance and thus permits 
diet relaxation  [9] . Deficiencies have been reported in 
responsive patients on a relaxed diet, who might experi-
ence difficulties making food choices after years of strict 
dieting  [7] .
 To optimize treatment, and to prevent deficiencies or 
potential toxic concentrations of micronutrients, there is 
a need for more insight into the nutrient intake and blood 
concentrations in PKU  [5] .
 Furthermore, a decreased bone mineral density (BMD) 
has been frequently reported in PKU patients on treat-
ment, and our meta-analysis demonstrated a slight de-
crease in BMD Z-score in PKU patients  [10] . One theory 
is that this might be due to micronutrient deficiencies.
 Our main objective was to evaluate the intake of mi-
cronutrients and essential fatty acids (FA) from natural 
protein-containing food and AAM in patients with PKU, 
and to investigate the association between intake and 
blood concentrations of these nutrients. The secondary 
objectives were to investigate BMD and fracture history, 
and their associations with blood concentrations and in-
take of micronutrients and essential FA.
 Methods 
 Study Design 
 This cross-sectional multicenter study was performed in 
3 Dutch metabolic centers (Academic Medical Center  Amsterdam 
[ n = 43], Maastricht University Medical Center [ n = 7] and 
 Groningen University Medical Center [ n = 10]) between May 
2013 and May 2014. The inclusion criteria were: PKU diag-
nosed through newborn screening; age  ≥ 1 year; continuous treat-
ment with a protein-restricted diet using an AAM, a protein-re-
stricted diet with AAM in combination with BH4 treatment or 
BH4 treatment without dietary protein restriction. While the ex-
clusion criteria were: changes in AAM within a month before in-
clusion and (planned) pregnancy. The study protocol was ap-
proved by the Ethics Committee of the AMC and patients/parents 
provided informed consent before participation.
 Micronutrients and essential FA were assessed in blood after 
>3 h fasting. An investigator-designed-questionnaire (online 
suppl. 1; for all online suppl. material, see www.karger.com/
doi/10.1159/000465529) was used to evaluate daily dietary in-
takes, fracture history and amount of physical activity (sports, 
walking and cycling in the past year). Medication (including 
BH4) and dietary intake of AAM/natural diet and supplementary 
vitamins/minerals were assessed. Patient reported intake was 
compared with the most recent dietary prescription from the 
treating dietician  [11] . Patient records were studied to obtain Phe 
concentrations from dried blood spots over the last 12 months, 
and BMD Z-scores from dual-energy X-ray absorptiometry scans 
(DXA) performed between 2 years before to 6 months after inclu-
sion.
 A sample size calculation was performed to determine the min-
imal number of patients, to detect differences of at least 1 SD be-
tween patients and normal values in serum levels of selenium, plas-
ma and erythrocyte levels of docosahexaenoic acid (DHA) and 
BMD. The minimum number of patients to be included resulted 
in 7 patients per age-group (to reach significance with type I error 
rate of 0.01 and type II error rate of 0.20 and based on a desired 
power of the study of 80%).
 Laboratory Measurements 
 Chemical analyses of micronutrients were performed at one 
particular clinical chemical laboratory for serum albumin, calci-
um, phosphate, magnesium, sodium, potassium, transferrin, sele-
nium, zinc, folic acid, 25-OH vitamin D2 + D3, vitamin B12, and 
whole blood vitamin B1 and B6, and for erythrocyte FA. We com-
pared the patient data with the reference ranges provided by the 
laboratory. These reference values are based on large groups of 
control patients and have been validated by our lab. Plasma AA 
was assessed at the medical center where the patient was under 
treatment because all laboratories participate in a quality control 
system for AA measurements.
 Detailed information about all laboratory analyses is available 
in the online supplementary material (online suppl. 2).
 Bone Mass Density Measurements 
 Patient BMD outcomes were compared to BMD reference data 
from the general Dutch population using Hologic Discovery Imag-
ing equipment. Details on the used reference data for children are 
presented in an article by van der Sluis et al.  [12] , who examined 
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 Society for Clinical Densitometry (ISCD), a diagnosis of osteopo-
rosis in children, men and premenopausal women is based on a 
BMD Z-score <–2 coupled with a significant fracture history  [13] .
 Dietary Intake and Growth Parameters 
 Weight/height were collected, and age/gender appropriate Z-
scores were calculated based on Dutch population references  [14] . 
Based on the answers provided by patients to the questionnaire, 
the daily intake of micronutrients, protein and fat was calculated 
manually. The questionnaire was orally assessed during a routine 
clinic visit. Results were compared to the recommended daily di-
etary allowance  [15] , and the safe advised range (SAR) of intake as 
recommended by the European Food Safety Authority  [16] . The 
recommended dietary allowance is based on ±2 SD of the required 
dietary intake and thus provides sufficient intakes for 97.5% of the 
general population  [17] .
 Statistical Analysis 
 For all analyses, the Statistical Package for Social Sciences Win-
dows version 19 was used. Descriptive statistics were used to assess 
intakes and blood concentrations of micronutrients, AA, FA and 
BMD Z-scores. Concerning laboratory concentrations and dietary 
intake, we decided that concentrations/amounts outside of the ref-
erence range are of interest to study (remarkable). The reference 
range provides mean ± 2 SD for a healthy age-matched population; 
hence, remarkable results represent concentrations below 2.5% or 
above 97.5% of normal. Results are reported as median values and 
the range has been specified; data are shown separated in age 
groups equal to available age groups used to indicate reference 
ranges. In addition, Mann–Whitney U (not normally distributed 
continuous variables) or chi-square tests (nominal data) were con-
ducted to test differences between patients based on disease sever-
ity, BH4 and supplement use (not AAM). Because most data dem-
onstrated a non-normal distribution, those data distributed nor-
mally were treated as if they were not. The applied significance 
level was  p = 0.01.
 Results 
 Participants 
 Sixty out of 102 eligible patients (58.8%) agreed to par-
ticipate in the study. One enrolled patient was not includ-
ed in the dietary analyses, because the answers given in 
the questionnaire were inconsistent with the prescribed 
intake. Of the included 60 patients, the median age was 
13 years (range 1–39 years) and 25 (41.7%) were male. No 
differences were found between male and female patients 
for all assessed outcomes. None of the participants had 
restricted mobility, or used medication that affected the 
bone status. Medications used (other than BH4) ranged 
from bronchodilators used for asthma to paracetamol 
used for reducing pain and fever. Detailed patient char-
acteristics are displayed in  Table 1 .
Table 1.  Patient characteristics




Male, n (%) BMD, Z-score (SD)
Population
All 60 (100) 13.0 (6–17) 25 (41.7) 0.45 (–0.18 to 1.24)
1–11 25 (41.7) 6.0 (4.5–9) 10 (40) 0.45 (0.08 to 0.96)
12–17 20 (33.3) 15 (13.3–15.8) 10 (50) 0.42 (–0.49 to 1.06)
18–39 15 (25) 29 (20.8–35.8) 5 (33.3) 0.49 (–0.40 to 2.65)
Age, years n Total protein intake, 
median (IQR)
Protein natural sources, 
median (IQR)





All 59 64.8 (43.1–76.6) 14.6 (10.1–26.4) 55 45.00 (25.2–62.2) 14 (24)
1–11 24 39.7 (34.5–58.1) 10.8 (7.9–25.4) 23 25.2 (15.2–39.0) 7 (28)
12–17 20 74.7 (63.9–83.5) 16.3 (12.0–27.3) 19 60.0 (40.0–63.0) 5 (25)
18–39 15 81.3 (72.5–86.1) 19.0 (12.5–28.2) 13 60 (50.5–71.7) 2 (14)
 Age, years n Plasma Phe values, 
μmol/L, median (IQR)
Percentage of bloodspot 
Phe values above range 
per patient, median (range)
Phenylalanine
1–11 24 302 (193–342) 33 (0–67.5)
12–17 20 611 (401–778) 57 (0–100)
18–39 15 804 (522–978) 60 (0–100)
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 Protein Intake, Phe Concentrations and BH4 Use 
 Detailed information on protein intake and Phe 
concentrations is shown in  Table 1 . All patients had a 
total protein intake above minimal safe recommenda-
tions. Twenty-four percent of patients had a Phe toler-
ance of <500 mg per day (severe phenotype). Fourteen 
patients used BH4; 10/14 had an additional natural pro-
tein restriction and AAM, 4/14 were off diet. Twenty-
five different AAM were used, most frequently  Milupa 
PKU-2-prima ( n = 11), Milupa PKU-2-mix ( n = 10), 
Vitaflo PKU cooler ( n = 9) and Milupa PKU-3-advan-
ta ( n = 6).
 The median percentage of Phe measurements above 
the recommended range in the year before inclusion var-
ied from 33 to 60%, increasing with age ( Table 1 ); com-
parable to findings in other cohorts of PKU patients  [18, 
19] .
 Laboratory Results 
 Laboratory results of 2 patients were incomplete: in 
one AA were not evaluated and in the other only vita-
mins and FA were measured. The laboratories assess-
ing AA made different choices on AA measured in rou-
tine PKU follow up, and therefore the total num-
ber  of  assessed samples differs. We report levels 
outside of reference ranges with possible clinical impli-
cations;  tables demonstrating unremarkable intake and 
laboratory findings are available in online supplements 
3–6.
 Micronutrients 
 Out of range dietary intakes and blood levels are re-
ported in  Tables 2 and  3 , respectively.
 Vitamin D 
 Vitamin D (vitD) intake was below the advised mini-
mum intake of 5 μg/day  [20] in 12/59 (20%) patients. 
VitD supplements were used in 12/60 (20%) patients. 
The 25-OH vitamin D2 + D3 serum level was below the 
reference range of 50 nmol/L in 7/59 (12%) patients (4 
using AAM, 3 without dietary restrictions) and below 25 
nmol/L in 2 of them (3%). The 2 patients with the lowest 
serum concentrations (21 nmol/L) reported very low in-
takes: one adult using AAM not containing VitD 
(Phlexyvits) had a dietary intake of 0 μg/day; one adult 
using BH4 had a natural protein intake of 64.7 g/day 
with a VitD intake of 0.80 μg/day. Of the 11 patients us-
ing oral vitD supplements, 7 used over-the-counter 
 supplements, 3 had a prescription from their general 
practitioner and 1 patient had a prescription from the 
metabolic specialist. Three more patients used over-the-
counter multivitamin supplements containing vitD. No 
significant differences in serum concentrations were 
found between supplemented and un-supplemented pa-
tients (72 vs. 70 nmol/L).
Table 2.  Dietary intake
Age, years Total, n Range Median Above 
SAR, n
Zinc, mg/day
1 3 4–21 7 2
4–8 14 6–14 10 8
9–13 13 9–34 24 7
≥14 (male) 12 2–25 17 8
≥14 (female) 17 5–32 17 6
Selenium, μg/day
1 3 11–38 25 –
4–8 14 8–56 24 –
9–13 13 26–91 51 –
≥14 (male) 12 5–125 58 –
≥14 (female) 17 30–125 78 –
Magnesium, mg/day
1 3 92–276 132 –
4–6 12 107–375 251 –
7–10 9 151–411 277 –
11–18 (male) 12 139–701 386 –
11–18 (female) 11 299–647 487 –
≥19 (male) 4 432–667 495 –
≥19 (female) 8 363–644 503 –
Folic acid, μg/day
1 3 70–313 127 1
4–6 12 116–380 240 3
7–10 9 137–484 296 2
11–14 9 285–577 457 –
≥15 26 131–1,256 477 2
Vitamin D, μg/day
All 59 0–40 11 –
Vitamin B6, mg/day
1 3 0.7–2.3 0.9 –
4–6 12 0.8–3.8 1.8 –
7–10 9 0.8–3.4 1.8 –
11–18 23 0.8–5.7 2.4 –
≥19 (male) 4 2.3–3.8 3.1 –
≥19 (female) 8 2.2–4.0 3.1 –
Vitamin B12, μg/day
1 3 1–2.4 1.1 –
4–6 12 1–4.3 1.7 –
7–10 9 2.5–3.8 3.3 –
11–18 22 2–7 3.9 –
≥19 12 3.2–7.6 4.8 –
Fat, % caloric intake
1 3 25–37 31 –
4–17 42 8–46 20 –
≥19 14 6–38 14 –



















   
   
   
   
   
   
   
   
   

























 The daily selenium intakes varied from 5 to 125 μg/day, 
and 27 patients (45%) had low serum concentrations 
(7/27 using BH4 with AAM). Of these, 13/27 patients 
(48%) had a selenium intake below and 6/27 (22%) had an 
intake above the advised range. None of the patients had 
an intake above the SAR. The 2 patients with the highest 
intake (125 μg/day) were females (aged 14 and 30 years) 
with a mild phenotype. The majority of selenium was in-
gested through the use of AAM.
 No significant differences in serum concentrations 
were found between supplemented (6/60, 10%) and un-
supplemented patients (0.87 vs. 0.80 μmol/L).
 Zinc 
 Despite the dietary zinc intake being well above the 
norm in 48/59 patients (81%), low serum concentrations 
were found in 8/59 patients (14%, none using BH4). Only 
one of these patients had a dietary intake below the ad-
vised range and 5 had an intake above SAR. Severe pa-
tients showed significantly higher median zinc concen-
trations than mild patients: 12.5 vs. 10.6 μmol/L.
 Folic Acid, Magnesium, Vitamin B6 and Vitamin B12 
 Patient’s intakes of folic acid, magnesium, vitamin B6 
and B12 were above the advised range. Folic acid intake 
was above SAR in 5/26 patients (9%) and serum concen-
trations were above reference range in 26/56 (46%). Pa-
tients used the following supplements: magnesium ( n = 
1), multivitamin tablets ( n = 4), vitamin B complex ( n = 
1). High blood concentrations were also found for mag-
nesium (9/59, 15%), vitamin B6 (52/60, 89%) and vitamin 
B12 (11/58, 19%). Patients off diet treated with BH4 did 
not show elevated magnesium and folic acid concentra-
tions ( n = 5). Severe patients (who inherently use more 
AAM than mild patients) showed significantly higher 
concentrations of vitamin B12 (median 600 [ n = 13] vs. 
482 pmol/L [ n = 44]), indicating that vitamin B12 is high-
ly available in used AAM. No significant differences were 
found between supplemented and un-supplemented pa-
tients for folic acid, magnesium, vitamin B12 and B6.
 Amino Acids 
 Plasma concentrations were below reference ranges for 
asparagine (22/59, 37%), 2-aminobutyric acid (10/50, 
20%), tyrosine (13/59, 22%) and arginine (33/58, 57%). 
Plasma hydroxyproline concentrations were elevated 
(11/40, 28%), as were ornithine concentrations (16/59, 
27%;  Table 4 ). Phe concentrations were high in all ages. Low 
asparagine was significantly more often found in patients 
using BH4 (2/15 vs. 20/44 not using BH4, or 13 vs. 45%).
 Erythrocyte FA 
 Patient’s daily total fat intake was below the minimal 
recommended 20% of caloric intake in 34/59 (58%) pa-
tients. Thirteen of these 34 patients (38%) used AAM 
Table 3.  Blood concentrations of 25-OH vitamin D2 + D3, selenium, zinc, folic acid, vitamin B6, vitamin B12, and magnesium
Total, n Range Median  Compared to reference range, n
ab ove within below
Vitamin 25-OH D2 + D3, 
nmol/L
All patients 59 21–195 70 – 52 7
Extra supplementation 12 21–148 66 – 8 4
No extra supplementation 47 21–195 70 – 44 3
Selenium, μmol/L
All patients 59 0.5–1.4 0.8 – 30 29
Extra supplementation 53 0.5–1.4 0.8 – 28 25
No extra supplementation 6 0.6–1.3 0.9 – 2 4
Zinc, μmol/L
All patients 58 6.5–19.6 12.4 1 49 8
Magnesium, mmol/L
All patients 59 0.8–1.0 0.87 24 35 –
Folic acid, mmol/L
All patients 56 10.7–45.5 38.7 29 27 –
Vitamin B12, mmol/L
All patients 58 176–862 518.5 11 47 –
Vitamin B6, nmol/L
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without added FA, 19 (56%) used AAM with added FA, 
and 2 patients were off diet (6%;  Table 2 ).
 All patients had total erythrocyte FA concentrations 
within the reference range. Concentrations of essential 
FA linoleic acid (LA; C18: 2ω6) and α-linolenic acid 
(ALA; C18: 3ω3) were unremarkable. Elevated concen-
trations (in up to 38% of patients) were found for homo-
γ-linolenic acid (C20: 3ω6), docosatetraenoic acid (C22: 
 4ω6), docosapentaenoic acid (C22: 5ω6) and DHA; c22: 
 6ω3. For eicosapentaenoic acid (EPA; C20: 5ω3), 10/60 
patients (17%) showed low concentrations ( Table 5 ).
 Median DHA and EPA concentrations were higher 
both in patients using FA-supplemented AAM and in pa-
tients on a free diet, when compared to patients using 
AAM without FA supplementation (DHA 23 and 22 vs. 
16.5 pmol/10E6 cells; EPA 2.7 and 2.4 vs. 2.1 pmol/10E6 
cells).
 Bone Mass Density and Fracture History 
 Mean Z-scores for lumbar, femoral and hip BMD 
were overall normal with Z-scores <–2 in 4.9% ( n = 
2/41), 7.4% ( n = 2/27) and 5.9% ( n = 2/34) of patients, 
respectively ( Fig. 1 ). Median Z-scores by age are shown 
in  Table 6 . No differences in BMD were found based on 
BH4 use or severity of disease. The median physical ex-
ercise for adults was 205 min/week, for children 12–
17 years 325 min/week and those 1–11 years 180 min/
week.
 A total of 25 patients (41.7%) suffered one or more 
fractures. All fractures were caused by compatible trauma 
and healed without complications. No vertebral fractures 
were noted. One patient had a positive fracture history as 
defined by the ISCD; however, the BMD was within nor-
mal range.
Table 4.  Amino acids in plasma, μmol/L
Age, years Total, n Range Median  Compared to reference range, n
above within below
2-Aminobutyric acid
1 3 10–16 13 – 3 –
2–9 16 7–18 10.5 – 7 9
10–17 19 5–27 12 – 18 1
≥18 12 10–19 11 – 12 –
Tyrosine
1 3 22–129 74 1 2 –
2–9 17 23–118 53 1 11 5
10–17 24 18–103 43.5 2 12 10
≥18 15 31–111 65 3 11 1
Arginine
1 3 14–60 25 – 2 1
2–9 17 21–66 45 – 12 5
10–17 23 24–62 41 – 7 16
≥18 15 8–64 33 – 4 11
Ornithine
1 3 50–97 87 – 3 –
2–9 17 30–96 65 10 7 –
10–17 24 35–96 67.35 3 21 –
≥18 15 43–123 73 5 10 –
Asparagine
1 3 17–40 32 – 2 1
2–9 17 18–48 33 – 15 2
10–17 24 20–48 32.5 – 15 9
≥18 15 23–41 31 – 5 10
Hydroxyproline
1 3 11–19 14 – 3 –
2–9 15 8–22 12 5 10 –
10–17 24 10–208 18.5 6 18 –



















   
   
   
   
   
   
   
   
   

























 We evaluated the dietary intake and deficiencies of mi-
cronutrients and essential FA, BMD, physical activity and 
fracture history in a large group of patients with PKU. It 
is very reassuring that in spite of the complex diet, most 
blood concentrations of micronutrients are in the normal 
range. Some exceptions need to be addressed specifically.
 Micronutrients 
 Vitamin D 
 To investigate the bone status in our patients, we eval-
uated the intake and blood levels of calcium and vitD, 
measured BMD and assessed the amount of physical ex-
ercise. Calcium intakes and levels in blood were within 
the required range, and BMD outcomes are discussed be-
low. VitD status was evaluated by measuring the serum 
vitamin 25-OH D2 + D3 as advised  [21] . Serum 25-OH 
vitamin D2 + D3 levels were below the reference range in 
14% of patients, fully comparable to individuals in the 
general population  [20–22] and patients with PKU who 
are off diet in whom concentrations below reference 
range are also frequently observed  [23] . Of the 2 patients 
showing concentrations in the range associated with clin-
ical symptoms (<25 nmol/L  [19, 20] ), 1 patient had a nor-
mal intake of natural protein. There was no difference 
found between patients with and without extra supple-
mentation of vitD. This may be due to the fact that serum 
vitamin 25-OH D2 + D3 is affected not only by vitD in-
Table 5.  Erythrocyte essential fatty acids: ALA and metabolites, pmol/10E6 cells
Total, n Range Median  Compared to reference range, n
above within below
C18:3ω3 LA
All patients 60 0.0–1.7 0.9 7 46 7
FA in AAM 35 0.0–1.7 0.9 5 28 2
No FA in AAM 20 0.0–1.6 0.8 2 14 4
Off diet 5 0.3–1.0 0.8 – 4 1
C20:5ω3 EPA
All patients 60 0.5–4.9 2.4 – 47 13
FA in AAM 35 0.5–4.9 2.7 – 31 4
No FA in AAM 20 0.7–3.5 2.1 – 12 8
Off diet 5 1.6–3.6 2.4 – 4 1
C22:5ω3 docosapentaenoic acid
All patients 60 7.2–23.6 11.6 15 45 –
FA in AAM 35 7.2–19.0 11.6 8 27 –
No FA in AAM 20 8.7–23.6 11.6 7 13 –
Off diet 5 9.8–13.4 11.2 – 5 –
C22:6ω3 DHA
All patients 60 9.2–42.4 19.7 10 50 6
FA in AAM 35 9.3–42.4 22.6 10 24 1
No FA in AAM 20 9.2–23.9 16.3 – 14 5
Off diet 5 16.2–25.0 22.2 – 5 –
 ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linolenic acid; FA, fatty acids; AAM, amino-
acid mixture.











n = 34 n = 27 n = 41
BMD Z-score




















   
   
   
   
   
   
   
   
   





















 Demirdas   et al. Ann Nutr Metab 2017;70:111–121
DOI: 10.1159/000465529
118
take, but also by genetic factors, sunlight exposure and 
supplement intake adherence  [24] .
 The normal concentrations found in most patients are 
due to proper monitoring and, if necessary, supplementa-
tion. Therefore, we advise to yearly evaluate intake and 
determine blood concentrations, and to supplement pa-
tients when levels are <50 nmol/L (or as according to cur-
rent guidelines)  [20–22, 25] .
 Zinc 
 Zinc serum concentrations were below the reference 
range in 14% of patients, despite an intake above SAR in 
52% of patients. This finding is comparable to outcomes 
in other studies  [5, 7, 8] . However, the clinical relevance 
of the observed low zinc concentrations is unclear. It 
seems probable that the severe restriction of natural pro-
tein in the PKU diet decreases zinc absorption, as a low 
intake of animal protein in a vegetarian diet may decrease 
the absorption of zinc  [26] . Zinc deficiency is associated 
with growth retardation and sexual maturation abnor-
malities, decreased wound healing, hair loss, diminished 
visual dark adaptation and anorexia  [27] . Hair loss has 
been described in other diseases than PKU at serum levels 
below 11 μmol/L (72 μg/dL)  [28] and skin lesions below 
9.2 μmol/L (60 μg/dL)  [29]. We have not assessed these 
problems in our population, but if certain symptoms are 
encountered in patients with PKU combined with de-
creased zinc blood levels, supplementation could be con-
sidered. Future studies need to explore how to effectively 
increase the zinc uptake in PKU patients of whom many 
already have intakes exceeding SAR.
 Selenium 
 Low plasma selenium serum concentrations, as seen in 
46% of our patients, have previously been reported in 
PKU  [7, 8] . Plasma selenium is an adequate biomarker for 
assessing the selenium status in patients on a special diet 
 [30] . Selenium is best absorbed as an organic form, while 
inorganic forms, such as that used in AAM, are less well 
absorbed. This may also explain why there was no differ-
ence found between patients who used extra supplemen-
tation and those who did not. Selenium deficiency may 
lead to cardiomyopathy, depressive symptoms or osteo-
arthropathy  [30–33] . Elevated Phe values already put 
PKU patients at risk for mood disturbances  [34, 35] . 
 Because intake is low in many patients (41%), it seems 
advisable to annually evaluate the selenium status and 
consider supplementation if concentrations are below 
the advised reference ranges (supplementing up to 400 
μg/day is considered to be safe in adults  [36] ). However, 
the clinical relevance of our findings is unknown and it is 
yet unclear what amount of supplementation will be 
needed to achieve normal concentrations of selenium in 
the blood. Future studies are warranted.
 Folic Acid 
 Folic acid intake and blood concentrations were re-
markably high in patients using AAM. Five patients re-
ported an intake above SAR ( Table 2 ). Because all pa-
tients off diet showed serum concentrations within nor-
mal range, elevated serum concentrations appear to be 
due to fortified AAM  [37] . Our findings are confirmed 
by the study by Stolen et al. [38] reporting similar results. 
As there is discussion on the safety of high concentra-
tions  [38, 39], it deserves due consideration to lower folic 
acid amounts in AAM. For example, high levels of folic 
acid have been associated with interference in DNA and 
histone methylation, decreased natural killer cell toxici-
ty, an increased risk of cognitive impairment in the el-
derly and facilitating progression of preneoplastic cells 
and subclinical cancers. Because this micronutrient is 
highly available in several AAM, decreasing the concen-
tration of folic acid in these AAM may be advisable  [38, 
39] .
 Dietary intake and blood concentrations of magne-
sium, vitamin B6 and B12 are elevated. However, as in-
takes are within SAR and these micronutrients are not 
known to be toxic, adaptation of intake may not be war-
ranted  [15] . The fact that there is no difference in serum 
levels between patients using extra supplementation and 
those who do not is not surprising because intakes of the 
named nutrients are overall high.
Table 6.  BMD Z-scores by age
Age, years  Median BMD Z-score
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 Amino Acids 
 In some patients, low values of arginine, tyrosine, aspar-
agine and/or 2-aminobutyric acid were demonstrated. 
However, there was no indication of clinical implications. 
The low plasma arginine values did not result from hemo-
lysis as ornithine concentrations were normal. AAM use 
has been associated with plasma tyrosine fluctuations and 
effects of extra tyrosine supplementation on outcome are 
yet unclear  [40] . Furthermore, we do not have a clear expla-
nation as to why some of the non-essential amino-acids 
were low in plasma. They are fully supplemented in the ami-
no-acid mixtures, and we do not think that the minimum 
3 h fasting of our patients is attributable to the outcomes 
either. Future studies are warranted to investigate the need 
for increased supplementation of specific AA in PKU.
 Hydroxyproline (a bone resorption marker) was ele-
vated in adolescents, representing increased protein turn-
over in bone during growth  [41] .
 Erythrocyte FA 
 Essential FA are precursors of thromboxanes, leu-
kotrienes and prostaglandins  [42] . DHA and EPA are 
known to have cardio-protective effects  [43] and defi-
ciencies may lead to CNS disease or affect the im-
mune  system  [42] . Normal as well as reduced plas-
ma and erythrocyte FA levels have been reported in pa-
tients with PKU  [44–49] . It is, however, not clear 
what these deficiencies mean and if they have a clinical 
impact on the patients. In patients with PKU, altera-
tions in plasma/erythrocyte levels of FA have been as-
sociated with lowered BMD and neurological outcomes 
 [6] .
 Even though EPA and DHA are frequently supple-
mented in AAM, EPA is below reference concentrations 
in 6% of our patients. For this reason, it may be consid-
ered to increase EPA supplements in AAM. Significantly 
lower concentrations of DHA and EPA are found in pa-
tients using AAM without FA versus those using FA-sup-
plemented AAM. For this reason, it may be advisable to 
prescribe FA containing AAM or to supplement. Further 
research is needed to determine the optimal supplemen-
tation dosage and to establish beneficial functional out-
comes  [6] .
 Bone Health 
 We are one of the first to asses fracture risk and the 
amount of physical exercise in early treated patients with 
PKU in a cohort of this size. As mentioned, we retrospec-
tively collected BMD data obtained during standard clin-
ical care of patients with PKU. BMD was routinely and 
regularly assessed to detect low BMD as early as possible 
with the aim of preventing fractures. We found a lumbar 
and femoral BMD Z-score <–2 in 4.9 and 7.4% of our pa-
tients, respectively. None of the patients had osteoporosis 
as defined by the ISCD, and the lifetime fracture preva-
lence of patients seems comparable to the general popula-
tion (41, 7 vs. 38.2%)  [43] . These findings are in line with 
data reported in our recently published meta-analysis 
 [10] and support our recommendation to only perform a 
single assessment of BMD with DXA scan in adolescent 
patients with PKU. Only those patients with a BMD Z-
score <–2 and/or a significant fracture history may need 
follow-up. In this way, unnecessary radiation exposure 
may also be avoided.
 Physical exercise in adults met World Health Organi-
zation recommendations (150 min/week). Of children 
aged 12–17 years, 80% did not meet the recommended 
60 min/day of exercise, which is comparable to the gen-
eral population  [50] . We have no reason to believe that 
insufficient physical activity in this patient group has a 
negative effect on bone health other than it would in the 
general population.
 Study Limitations 
 Our study results are overall normal, and in treated 
patients the diet seems less shortcoming as has been hy-
pothesized in previous literature.
 However, this study was an uncontrolled study, covering 
a wide age range of patients on varying treatment options. 
Some micronutrient deficiencies were found, but based on 
our results we can unfortunately not conclude whether 
these deficiencies are based on shortcomings of the diet 
(AAM composition), on a lack of adherence of our patients, 
or on physiological consequences of the disease itself. Even 
though we present data of one of the largest cohorts pub-
lished, our study is limited by the low patient numbers and 
the diversity of the PKU severity/spectrum of disease. This 
has led to a heterogeneous group when it comes to dietary 
treatment and therefore dietary intake. For example, AAM 
used by our patients were diverse and a comparison of dif-
ferent types of AAM was therefore not possible.
 Multivariable Linear Regression 
 Unfortunately, we were not able to properly investi-
gate associations between blood and intake levels of as-
sessed nutrients, nor between outcomes of researched nu-
trients and BMD. However, because these relations are of 
great interest to achieve further knowledge on the etiol-
ogy of nutrient deficiencies and bone health, larger cohort 
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